ERA Banner
Download Add to Cart Share
More Like This
  • Reasons for not receiving standard of care treatment and effectiveness of capecitabine in stage III colon cancer patients in Alberta
  • El Shayeb, Mohamed
  • en
  • colon cancer
    standard of care
    comparative effectiveness
    adjuvant chemotherapy
  • Sep 30, 2011 6:16 PM
  • Thesis
  • en
  • Adobe PDF
  • 692619 bytes
  • Adjuvant chemotherapy is the standard of care for stage-III colon cancer. Despite this, large proportions of patients do not receive it; the oncologist may not recommend it or the patient may refuse it. We aimed to identify the physicians’ and patients’ reasons for making treatment decisions. We also evaluated the effectiveness of newly-introduced capecitabine in real clinical practice. A retrospective population-based study was conducted that included all surgically-treated stage-III colon cancer patients in Alberta between 2002 and 2005 who had consultation with an oncologist. Chart reviews were conducted to extract treatment details, oncologists’ reasons for not recommending, and patients’ reasons for declining chemotherapy. A total of 613 patients met the inclusion criteria. Overall, 27% of the patients did not receive chemotherapy. The most frequent reason for not recommending chemotherapy was co-morbidity. Twenty-two percent of patients declined treatment due to toxicity concerns. Effectiveness results of capecitabine conformed to its efficacy.
  • Master's
  • Master of Science
  • School of Public Health Sciences
  • Fall 2011
  • Yutaka Yasui (School of Public Health)
    Macy Winget (Cancer Care, Alberta Health Services)
  • Andrew Scarfe (Faculty of Medicine and Dentistry, Cross Cancer Institute)
    Yutaka Yasui ( School of Public Health)
    Marcy Winget (Cancer Care, Alberta Health Services)


Download license

Apr 30, 2014 6:14 PM


Mar 9, 2012 11:51 AM